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ABSTRACT
Hepatocellular carcinoma develops as a multistep process, in which cell cycle 
deregulation is a central feature, resulting in unscheduled proliferation. The PLAGL1 
gene encodes a homonym zinc finger protein that is involved in cell-proliferation 
control. We determined the genomic profile and the transcription and expression 
level of PLAGL1, simultaneously with that of its molecular partners p53, PPARγ and 
p21, in cell-lines derived from patients with liver cancer, during in vitro cell growth. 
Our investigations revealed that genomic and epigenetic changes of PLAGL1 are also 
present in hepatoma cell-lines. Transcription of PLAGL1 in tumor cells is significantly 
lower than in normal fibroblasts, but no significant differences in terms of protein 
expression were detected between these two cell-types, indicating that there is not a 
direct relationship between the gene transcriptional activity and protein expression. 
RT-PCR analyses on normal fibroblasts, used as control, also showed that PLAGL1 and 
p53 genes transcription occurs as an apparent orchestrated process during normal 
cells proliferation, which gets disturbed in cancer cells. Furthermore, abnormal 
trafficking of the PLAGL1 protein may occur in hepatocarcinogenesis.
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INTRODUCTION
Hepatocellular carcinoma (HCC) is the sixth 
most common cancer and the third cause of death 
cancer worldwide. HCC is widely distributed around 
the world, presenting higher incidence in sub-Saharan 
Africa and Eastern Asia than Northern Europe, Oceania 
and America [1]. This uneven geographical distribution 
is closely related to that of the risk factors which vary 
among regions. For instance, the hepatitis B and C virus 
infections are common in Asia and Japan, respectively, 
whereas obesity and non-alcoholic liver disease lead to 
an increased incidence of HCC in United States and other 
western countries [2].
HCC develops as a multistep process, in which 
multiple factors play a role creating the conditions for 
malignant transformation. For example, hepatitis B or C 
viruses infection lead to liver damage and regeneration 
events, in which the persistent inflammation and oxidative 
stress favour the occurrence of genomic instability 
leading to the accumulation of genetic and epigenetic 
alterations that are a hallmark of tumorigenesis [3, 4]. 
Cell proliferation is regulated by a complex network of 
signalling pathways, such as HGF/MET, Wnt/β-catenin 
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and p53, among others [5, 6]. Structural and/or functional 
alterations of proteins that participate in these pathways, 
leading to cell-cycle deregulation are frequently found in 
HCC cells [7]. For example, mutations in the CTNNB1 
gene, encoding for an abnormal β-Catenin protein, have 
been found in about 30% of HCC biopsies analyzed by 
Schulze et al. in 2016 [8]. While in vitro studies, using 
the HepG2, SkHep1 and Huh7 cell lines derived from 
human heptomas demonstrated that down-regulation of 
the COMMD7 gene and the treatment with isocorydine 
and interferons favour inhibition of cell proliferation and 
induction of apoptosis [9–11]. 
The PLAGL1 (Pleiomorphic Adenoma Gene-
Like 1) gene maps on chromosome 6q24 [12], and it 
encodes a homonym zinc finger protein that functions as 
a transcription factor and as a cofactor of other proteins 
involved in cell cycle control [13]. PLAGL1 carries on 
its activities through convergent mechanisms. On one 
hand, it interacts with p53 and this heterodimer induces 
the expression of the receptor for pituitary adenylyl 
cyclase-activating peptide (PACAP1-R). The binding 
peptides to PACAP1-R induce gene transcription through 
AP-1, essential for proliferation and differentiation 
of various cell types [14]. Moreover, PLAGL1 and 
p53 bind as a complex to the promoter of p21 gene, an 
important cell cycle regulator; favouring its transcription 
and leading to cell cycle arrest in G1 phase [15, 16]. 
On the other hand, PLAGL1 induces the expression of 
PPARγ that inhibits cell cycle progression through p21 
induction and metastatic activity through the regulation 
of matrix metalloproteinases expression [17, 18]. It 
was demonstrated that genomic changes such as loss of 
heterozygosity (LOH) and hypermethylation of the P1 
promoter of the PLAGL1 gene are frequently observed in 
several types of cancer such as pheochromocytoma [19], 
ovarian cancer [20], breast cancer [21], pituitary adenomas 
[22] and hemangioblastoma [23], and in tumor cell lines 
including breast cancer cell lines [21]. Moreover, altered 
expression of PLAGL1, mainly reduced, was revealed in 
colorectal cancer and non-functioning pituitary adenoma 
[24, 25]. Midorikawa et al. examined samples of HCC, 
and found that LOH at chromosome 6q, hypermethylation 
of PLAGL1 promoter at the remaining allele and low RNA 
expression levels were present in their series [26]. Since it 
was first described, the gene has been considered a tumor 
suppressor gene (TSG) [27], and all this evidence provided 
support for such classification. However, overexpression 
of PLAGL1 was detected in some human neoplasms such 
as glioma and clear cell renal cell carcinoma suggesting an 
oncogenic function, as well [28, 29].
In the present study we investigated the profile 
of 6q2 aberrations, where PLAGL1 gene maps, in four 
hepatoma cell-lines and the transcription and protein 
expression level of PLAGL1 and its molecular partners 
p53, PPARγ and p21 during in vitro cell-proliferation. 
Our data confirm that genomic and epigenetic changes of 
PLAGL1 are also present in HCC cell-lines. Furthermore, 
we found that there is not a direct relationship between 
the gene transcriptional activity and protein expression 
during cell-proliferation and that abnormal subcellular 
localization of the PLAGL1 protein may occur during 
hepatocarcinogenesis. 
RESULTS
Array-CGH analysis
Except for PLC/PRF/5 cells, all hepatoma cell-
lines exhibited an aberrant genomic profile at 6q24.2, 
where the PLAGL1 gene maps. Huh7 cells have losses of 
genetic material from almost the whole chromosome 6, 
but gains of the chromosome region 6q22.2. SkHep1 
cells showed losses of genetic material from the long 
arm of chromosome 6, and a specific amplification 
of 6q25.2. These cells also have gains of the short arm 
of the chromosome 6, but with punctual deletions at 
6p21.32 and 6p21.33. Regarding the region 6q24.2, the 
log-ratios for Huh7 and SKHep1 cells were −1.368 and 
−0.582, respectively, indicating that both tumor cell lines 
presented losses at the locus of PLAGL1 gene. On the 
contrary, HepG2 cells exhibited gains of the short arm of 
chromosome 6, while the long arm presented a punctual 
loss at q14 and gains of the region q22-qter. This cell line 
showed positive values of logratio (≈0.500) of the probes 
used specifically for the fragment 6q24.2 where PLAGL1 
maps, thus indicating gain of material. Finally, the 
hepatoma cell line PLC/PRF/5, apart from few punctual 
gains and losses in other chromosomes, did not present 
changes at chromosome 6 (Figure 1 and Table 1). 
The genome regions where the p53, PPARy and 
p21 genes map were also studied by aCGH in the four 
cell lines. The tumor suppressor gene p53 maps on 
chromosome 17p13.1 and the analysis demonstrated 
that this region is amplified in SkHep1 (logratio value 
= 0.398), while in the other hepatoma cell-lines Huh7, 
HepG2 and PLC/PRF/5 no abnormalities were detected. 
Regarding the PPARy gene (3p25.2), HepG2, Huh7 and 
PLC/PRF/5 did not exhibit quantitative changes, but the 
analysis of SkHep1 revealed loss at this region (logratio 
value = −0.571). The data obtained for the region where 
the p21 gene maps (6p21.31) are consistent with gains 
of genetic material in the HepG2 and SkHep1 cell-lines 
(logratios values = 0.517 and 0.277, respectively). In PLC/
PRF/5 cells aberrations at 6p2 were not detected, while in 
Huh7 a logratio value of −1.277 indicates losses of this 
chromosome region (Table 1). 
Out of 11 tissue-samples from patients with primary 
liver tumors, seven yielded quality DNA for aCGH. The 
analysis of quantitative genomic alterations revealed 
log-ratios compatible with losses at 6q24.2 (PLAGL1) in 
three of them: H008, H010 and H005 (Table 2). While 
all analyzed tumor samples did not present abnormalities 
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on the chromosome regions where the p21 and p53 genes 
map.
Methyl specific PCR
To study the methylation state of the P1 promoter 
of the PLAGL1 gene we performed MS-PCR. All cell 
lines presented a fraction of DNA methylated and another 
unmethylated. However, conspicuous differences in terms 
of intensity of the bands corresponding to these fractions 
were observed after gel electrophoresis in three cell lines. 
HepG2 was the only cell line in which the DNA-band 
of methylated P1 promoter was rather similar to that of 
unmethylated promoter, whereas in the SkHep1, Huh7 
and PLC/PRF/5 cell lines the methylated DNA fraction 
was much more intense than the unmethylated fractions 
(Figure 2).
Proliferation assays and flow cytometry
To estimate the proliferation capacity of the cell-
lines, the number of cells at different time points during 
culturing was determined, and used to calculate the 
doubling time (DT). Among tumor cell-lines, PLC/PRF/5 
cells were the most prolifertive; our DT calculation 
showed that these cells duplicated their number after 23 h 
Figure 1: Chromosome 6 genomic profile of the cell-lines SkHep1, HepG2, PLC/PRF/5 and Huh7. The green colour on 
the chromosome ideogram indicates loss of the fragment, the red indicates gain and the grey indicates a balanced status.
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of culture. SkHep1 cells were also highly proliferative 
(DT = 26 h), both cell-lines reached confluence faster 
than HepG2 and Huh7 whose DT were 29 h and 27 h, 
respectively. Fibroblasts had low proliferation capacity 
compared to tumor cells, and this is reflected by the high 
DT (59 h) (Figure 3A). To further study the proliferation 
capacity of the tumor cells, the amount of cells in the 
different phases of the cell cycle were determined by 
flow cytometry. The percentage of cells in the G2/M 
phase of the cell cycle increased from the beginning of 
the experiment (T = 0 h) until 48 h in culture, and from 
this time-point forward the fraction of cells in this stage 
decreased in all cell-lines. However, this analysis showed 
that during the entire assay the tumor cell-lines always 
presented higher percentage of cells in the G2/M phase 
than non-tumoral fibroblasts. Accordingly, the amount of 
fibroblasts in G1 phase was always higher than tumor cells 
(Figure 3B–3F).
PLAGL1, p53 and PPARy transcription 
mRNA levels of the PLAGL1, p53 and PPARy 
genes in all cell types and at the different time points 
during proliferation were estimated by quantitative RT-
PCR, and expressed respect to the level of the PPIA gene. 
Then we compared the transcript levels of PLAGL1, p53 
and PPARy of each tumor cell line with those obtained 
for fibroblasts at the same time point of the proliferation 
curve. This study showed that PLAGL1 and p53 transcript 
levels were in general significantly lower in all HCC 
Table 1: Genomic profile of the chromosome regions where the PLAGL1, p53, PPARy and p21 genes map in four 
hepatoma cell-lines
Cell line
Gene
PLAGL1 p53 PPARy p21
HepG2 0.507 0.000 0.000 0.517
SkHep1 −0.582 0.398 −0.571 0.277
Huh7 −1.368 0.000 0.000 −1.277
PLC/PRF/5 0.000 0.000 0.000 0.000
Positive values of the log-ratios indicate gain of genetic material, negatives indicate losses and 0.000 means absense of 
genomic abnormalities.
Table 2: Summary of the aCGH and in situ PLAGL1 and p21 proteins expression data from primary liver tumors
Sample Diagnostic
aCGH Immunohistochemistry
PLAGL1 Logratio PLAGL1 p21
H001 HCC 0.000 − −
H002 HCC NA + −
H003 HCC 0.000 + −
H004 HCC NA +++ ++
H005 HCC -0.472 + −
H012 HCC 0.000 ++ +
H013 HCC NA ++ +
H008 FNH -0.422 + −
H009 CCC 0.000 ++ +
H010 HAC -0.605 ++ ++
H011 HAC NA +++ −
H015 Normal tissue NA +++ +++
The expression of PLAGL1 and p21 was evaluated in eleven tumor samples and one from normal liver tissue. Except two 
tumors, all exhibited lower level of PLAGL1, while expression of p21 in all of them was absent or lower than in normal 
liver tissue. HCC: hepatocellular carcinoma; FNH: focal nodular hyperplasia; CCC: cholangiocellular carcinoma; HAC: 
Hepatoadenocarcinoma. Negative values of the logratios indicate losses of genetic material, 0.000 means absense of genomic 
abnormalities and NA stands for not analyzed. Score of each marker was calculated as described in Materials and Methods: 
strong expression (+++), moderate expression (++), weak expression (+) and negative expression (−).
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cell-lines compared to fibroblasts, except for p53 
transcript level in HepG2 and Huh7 cells at 48 h and 72 h 
(Figure 4A and 4B). Statistics confirmed that PLAGL1 
transcript level of tumor cells was significantly lower than 
that of non-tumor cells (p < 0.05) (Figure 4A). This study 
also showed that PLAGL1 mRNA levels in SkHep1 and 
Huh7 were insignificant (expression value = 0.00) respect 
to fibroblasts (Figure 4A). On the contrary, the levels of 
PPARy transcripts were in general higher in HCC cells 
than in fibroblasts during proliferation. Moreover, this 
gene transcription was exceedingly higher in Huh7 cells 
than in the other tumor cell-lines (Figure 4C).
qPCR data was also utilized to perform a detailed 
analysis of the dynamic of PLAGL1, p53 and PPARy 
genes transcription in each cell line during proliferation. 
In fibroblasts, PLAGL1 mRNA level decreased after 
the release from serum starvation until T = 48 h and 
then gradually increased until the end of the experiment 
(T = 96 h) (Figure 5A). Among the tumor cell-lines, only 
SKHep1 cells exhibited a transcriptional profile similar 
to that of fibroblasts, i.e., a significant reduction of the 
PLAGL1 mRNA level until T = 72 h and then increased to 
levels statistically not different to that obtained at T = 0 h 
(Figure 5C). Whereas PLC/PRF/5, HepG2 and Huh7 cells 
did not show variations in the transcript levels of PLAGL1 
gene along the growth curves (Figure 5B, 5D and 5E). 
The PLAGL1 protein interacts, among others, with 
p53 for controlling cell proliferation [13]. Therefore, we 
wondered whether transcription of the genes encoding 
these two proteins would keep any relationship with each 
other. As mentioned before, we found that p53 mRNA 
level in fibroblasts decreased from T = 0 h until T = 48 h 
during the proliferation assay, and then gradually increased 
until T = 96 h, following a similar transcription pattern 
of PLAGL1 in this cell type (Figure 5A). Tumor cells 
presented different dynamics of this gene transcription 
along the proliferation curve. In PLC/PRF/5 cells p53 
gene transcript level decreased significantly after the 
release from serum starvation and remained at low levels 
during the proliferation assay (Figure 5B). In SkHep1 and 
HepG2 cells p53 transcription remained without changes 
during the proliferation experiment (Figure 5C and 5D). 
Huh7 cells, on the contrary, exhibited a significant, and 
sustained, increase in the level of p53 gene transcription 
respect to the mRNA level that this cell type had at T = 0 h 
of the experiment (Figure 5E).
Considering that PLAGL1 acts also as a 
transcription factor of the PPARy gene, RT-qPCR was 
performed to determine the transcript level of this gene 
during cell proliferation. This analysis revealed that in all 
cell lines the transcript level of PPARy decreased respect 
to the level at T = 0 h, and it remained low during the 
proliferation experiment (Figure 5). 
PLAGL1, p53 and p21 proteins expression
The expression levels of PLAGL1, p53 and p21 
proteins were determined in all cell-lines by Western blot 
analysis. We compared the data of PLAGL1, p53 and p21 
protein levels for each tumor cell-line with those obtained 
for fibroblasts at the same time point of the proliferation 
curve. Despite high variability in PLAGL1 expression 
was seen, the statistical analysis demonstrated that there 
were not significant differences in the expression level of 
PLAGL1 between tumor cells and fibroblasts (Figure 6A). 
Regarding to p53 protein, the comparisons showed that 
the expression level of this protein was significantly lower 
in tumor cell lines than in fibroblasts, except for Huh7 
Figure 2: MS-PCR of the genomic region corresponding to the P1 promoter of PLAGL1 gene. Gel electrophoresis of the 
PCR products showed that the methylated DNA-fraction is larger than the unmethylated. L, size marker; M, methylated; U, unmethylated. 
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cells after 48 h and 72 h in culture (Figure 6B). Similar 
analysis of the data obtained for p21 protein revealed that 
its expression level was significantly higher in fibroblasts 
than in tumor cell lines along the experiment (Figure 6C). 
The data was also analyzed for each cell-line individually. 
In fibroblasts, PLAGL1 and p53 protein levels did not 
experiment demonstrable changes during cell growth, 
except for PLAGL1 protein that exhibited a significant 
increase just at the end of the proliferation curve 
(T = 96 h) (Figure 7A). This is in clear contrast with the 
dynamics of PLAGL1 and p53 genes transcription, which 
experimented a significant reduction in their transcripts 
level after serum starvation and then increasing until 
T = 96 h (Figure 5A). The expression of p21 protein 
exhibited a different profile; statistically significant 
increases were detected at each time-point during 
fibroblasts proliferation (Figure 7A).
The tumor cell-lines showed a rather uniform 
expression level of PLAGL1 during the growth assays, 
except for SkHep1 cells that presented significant lower 
expression levels at 48 and 96 h of the experiment 
(Figure 7). As to the expression of p53 and p21 proteins, 
Figure 3: HepG2, Huh7, SkHep1 and PLC/PRF/5 cells proliferate faster than non-tumoral fibroblasts. (A) Aliquots of 
25 × 103 cells/ml were seeded in 4 flasks and cultured in 10 ml of DMEM medium containing 10% FBS for 24, 48, 72 and 96 h. At each 
time point, the cells were harvested, and their number counted in a Neubauer chamber. Fibroblasts have a constant growth during the 
experiment and reached 7.5 × 104 cells/ml at 96 h, in contrast to the 2.5–4.5 × 105 cells/ml reached by HCC cells at the same time point. 
(B–F) Show the percentage of cells in each phase of the cell cycle at 0 h, 24 h, 48 h, 72 h and 96 h, respectively.
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Figure 4: Transcript level of PLAGL1, p53 and PPARy during proliferation. The mRNA level of each tumor cell-line was 
compared with that of fibroblasts at the same time point of the proliferation curve. (A) PLAGL1. (B) p53. (C) PPARy. Bars represent mean 
± SD. Asterisks indicate that the mRNA levels compared are significantly different; *p < 0.05, **p < 0.001, ***p < 0.0001.
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we found different profiles among tumor cell-lines. In 
PLC/PRF/5 cells, these proteins levels experimented a 
reduction respect the values obtained at 0 h, but only the 
reduction of p53 expression reach statistically significant 
levels during proliferation (Figure 7B). In SkHep1 cells, 
p53 expression increased at 72 h and decreased at 96 h, 
while p21 expression doubled the level during proliferation 
(Figure 7C). The HepG2 cell-line presented similar 
levels of p53 protein expression in all the time-points of 
the proliferation curve, whereas p21 protein underwent 
a conspicuous increase of expression at 48 h and then 
returned to similar levels of that of the synchronized cells 
(Figure 7D). Finally, in Huh7 cells p53 protein expression 
level did not change along the experiment, and the p21 
protein was not detected by Western blot (Figure 7E).
PLAGL1 and p21 proteins expression in situ
The expression in situ of PLAGL1 and p21 
proteins was determined by immunocytochemistry in 
the four hepatoma cell-lines and fibroblasts. PLAGL1 
immunoreactivity was weakly detected in the cytoplasm 
of tumor cells, while in normal fibroblasts its expression 
was readily observed in the nucleus and the cytoplasm. 
As regard to p21 protein, nuclear immunoreactivity 
was detected in normal fibroblasts and in HepG2 and 
SkHep1 cells. While PLC/PRF/5 cells presented weak 
immunoreaction only in the cytoplasm, and it was not 
detected in Huh7 (Figure 8).
PLAGL1 and p21 proteins expression in situ was 
also assessed in ten tissue samples from patients with 
hepatic tumors by immunohistochemistry. The microscopic 
analysis revealed that, except for two (H004 and H011), 
all tumor samples had lower expression of PLAGL1 
protein than normal liver cells (Figure 9; Table 2). 
Moreover, we observed that the protein localized only 
in the cytoplasms of tumor cells, and that in one tumor 
(H011) the protein formed aggregated close to the nuclear 
membrane (Figure 9). As to the p21 protein expression, 
the microscopic exam revealed that in six out of the 11 
samples the protein was not detected, and the remaining 
had lower level of p21 expression than non-tumoral cells 
(Table 2). 
PLAGL1 protein overexpression 
To study the effect of PLAGL1 overexpression 
on HCC cells proliferation, we performed transfection 
assays in two tumor cell-lines (PLC/PRF/5 and HepG2) 
with a plasmid encoding the full-length protein. Despite 
of the low efficiency of the transfection method (about 
10% in both cell types), the PLAGL1 protein level 
increased significantly in cell transfected with prk7-
PLAGL1, respect to non-transfected cells (Figures 10 
Figure 5: PLAGL1, p53 and PPARy transcript level during in vitro cell growth. (A) Fibroblasts. (B) PLC/PRF/5. (C) SkHep1. 
(D) HepG2. (E) Huh7. The statistical comparisons were made between any given time point and T = 0 h for each cell line individually. Bars 
represent mean ± SD. Asterisks indicate that the difference is significant; *p < 0.05, **p < 0.001, ***p < 0.0001.
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Figure 6: Proteins expression in normal and tumor cells during proliferation. PLAGL1 (A), p53 (B) and p21 (C) proteins 
levels were determined, and compared with that of fibroblasts at each time point. Bars represent mean ± SD. Asterisks indicate statistically 
significant differences; *p < 0.05, **p < 0.001, ***p < 0.0001.
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Figure 7: Expressiont level of PLAGL1, p53 and p21 of each cell line during proliferation. The Western blot data 
corresponding to each time point was compared with that of T = 0 h. (A) Fibroblasts. (B) PLC/PRF/5. (C) SkHep1. (D) HepG2. (E) Huh7. 
A protein extract from fibroblasts (Fibr) was used as a signal control for the antibody p21. Representative blots are shown at the side of 
each graph. Actin was used as loading control. Bars represent mean ± SD. Asterisks indicate statistically significant differences; *p < 0.05, 
**p < 0.001, ***p < 0.0001.
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and 11). However, Western blot analyses performed to 
determine the p21 protein level revealed that it increased, 
in response to PLAGL1 overexpression, only in HepG2 
cells (Figures 11B, 11C), which harbour a wild type 
p53 gene. Simultaneously we investigated whether this 
overexpression of PLAGL1 protein affects proliferation 
of tumor cells, by determining the number of cells for 
each experimental condition after 30 hs post-transfection. 
We found that PLC/PRF/5 cells without transfection 
proliferated actively from 2.2 × 105 cell/ml at T = 0 hs 
to 4.2 × 105 cell/ml at T = 30 hs, while cells transfected 
with prk7-PLAGL1 reached 3.2 × 105 cell/ml at T = 30 hs. 
As mentioned before, HepG2 cells were the least 
proliferative, and this was confirmed with this experiment. 
Transfection of these cells with the prk7-PLAGL1 
construct almost arrested cell growth (1.70 × 105 cell/ml 
at T = 0 hs vs 1.75 × 105 cell/ml at T = 30 hs), compared 
with untransfected cells (2.5 × 105 cell/ml at T = 0 hs). 
DISCUSSION
PLAGL1 is a TSG involved in the pathogenesis of 
several tumor types, including ovarian, gastric, pituitary 
and colorectal cancer [20, 24, 25, 30, 31]. Considering that 
LOH at the PLAGL1 locus and hypermethylation of its 
P1 promoter occur more frequently than gene mutations, 
the mechanisms by which this gene participates in the 
tumorigenic process seem to be different from those of 
typical TSGs. In fact, punctual mutations of the PLAGL1 
gene were detected in only 71 (0.3%) out of 21,029 tumor 
samples of all kind registered in the Catalog of Somatic 
Mutations in Cancer (COSMIC; http://cancer.sanger.
ac.uk/cosmic). To add more complexity, it has been also 
reported that overexpression of PLAGL1 was detected 
in some human neoplasms such as glioma and clear cell 
renal cell carcinoma, suggesting an oncogenic function, 
as well [28, 29]. As regard to HCC, Midorikawa et al. 
Figure 8: Immunocytochemistry for PLAGL1 and p21 proteins in tumor and normal cells. Microscopic exam of 
the preparations revealed that PLAGL1 protein localized only in the cytoplasm of tumor cells, while p21 exhibited both nuclear and 
cytoplasmatic localization. Similar to Western blot analysis, this protein was not detected in Huh7 cells. (A) Fibroblasts; (B) PLC/PRF/5; 
(C) HepG2; (D) Huh7; (E) SkHep1; (F) Negative control. Magnification 1000× (A–E) and 400× (F). 
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Figure 9: Immunohistochemical analyses of PLAGL1 and p21 proteins expression in liver tumors. Representative 
photomicrograph of non-tumoral liver tissue stained with anti-PLAGL1 and anti-p21 antibodies (A). (B) H003. (C) H012. (D) H011. 
(E) Negative control. Weak or moderate expression of PLAGL1 and p21 proteins was observed in tumor samples compared to normal 
liver tissue. Note that both proteins were detected in the cytoplasm and nuclei of non-tumor liver, while PLAGL1 localized only in the 
cytoplasms of tumor cells. Magnification 1000× (A–D) and 400× (E).
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found that LOH at the chromosome region 6q24, 
hypermethylation of PLAGL1 promoter at the remaining 
allele and low mRNA levels were frequent in tissue 
samples from patients with hepatoma [26]. Therefore, we 
wondered how genomic imbalances at the chromosome 
region 6q24, where PLAGL1 gene maps, would affect 
the transcription and expression level of this gene, and 
ultimately how this influences the proliferative capacity 
of liver cancer cells. To this aim, we investigated the 
profile of 6q24 aberrations of the hepatoma cell lines 
HepG2, Huh7, PLC/PRF/5 and SkHep1. The aCGH 
analysis showed that Huh7 and SkHep1 cells present 
losses of genetic material at 6q24.2, HepG2 exhibited 
gains, and PLC/PRF/5 has no abnormalities in this region 
(Figure 1 and Table 1). Also three out of seven liver 
tumors we analyzed had losses of genetic material from 
this region. This data may suggest that abnormalities at 
this chromosome region are common in HCC, however 
it should be kept in mind that other regions, such as 1p, 
8p and 17p, are affected by imbalances more frequently 
[26, 32]. Moreover, these changes are not specific of 
this tumor type, losses at chromosome 6q have also been 
found, among others, in pheochromocytomas and gastric 
adenocarcinomas [31, 33]. We also determined that the 
regulator region of PLAGL1 (P1 promoter) is heavily 
methylated in the four hepatoma cell lines (Figure 2), 
and most likely this explain the low mRNA level of the 
PLAGL1 gene in these tumor cell lines (Figure 4A). 
Reduced transcription, due to hypermethylation of P1 
promoter of this gene, was already demonstrated in 
gastric adenocarcinomas and HCC [26, 31]. However, the 
relationship between genomic imbalances, the methylation 
status of the P1 promoter and the transcription level of 
this gene is apparently not direct. In fact, the tumor cell-
line HepG2 presents gain of genomic material at 6q24 
(Figure 1), the lowest degree of P1 promoter methylation 
(Figure 2), and still the transcript and expression level of 
PLAGL1 is similarly low to that of the other hepatoma cell 
lines (Figure 4A and Figure 6A).
The proliferation assays we performed by cell-
counting demonstrated that the HCC cells grow much 
faster than the normal fibroblasts used as control. 
Accordingly, flow cytometry analysis showed that 
during the entire assay, the four tumor cell lines always 
presented higher percentage of cells in the G2/M phase 
than non-tumoral fibroblasts. This results were somehow 
expected, since cell cycle deregulation, which results in 
unscheduled proliferation, is a common feature of human 
cancer. In this context we determined the mRNA and 
protein levels of PLAGL1, and the RT-qPCR analysis 
Figure 10: Overexpression of PLAGL1 protein in PLC/PRF/5 cells. (A) Immunofluorescence of transfected cells with an 
antibody anti-PLAGL1(Green). (B) Immunofluorescence of transfected cells with antibodies against PLAGL1 (Red) and p21 (Green). 
(C) Representative blots of PLAGL1 and p21 proteins. A protein extract from fibroblasts (Fibr.) was used as a signal control for the antibody 
against p21. Actin was used as loading control. (D) PLAGL1 relative expression: Control 1 = T: 0 hs; Control 2 = No plasmid; Control 
3 = Empty plasmid; PLAGL1 = PLC/PRF/5 cells transfected with the plasmid prk7-PLAGL1. Bars represent mean ± SD. Asterisks indicate 
statistically significant differences (***p < 0.0001). 
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revealed that transcription of PLAGL1 in tumoral cells 
is significantly lower than in normal fibroblasts, but no 
significant differences in terms of protein expression were 
detected between tumor cell-lines and normal fibroblasts. 
As mentioned before, reduced transcription of PLAGL1 is 
common to several tumor types [24, 25, 31], but the results 
of protein expression are intriguing. It is well accepted 
that the abundance of proteins may or may not keep a 
direct relationship with the mRNA levels because of the 
differences in the mechanisms regulating transcription 
and translation, and also that mRNAs are produced at a 
much lower rate, and are less stable than proteins [34], 
inclusive specific PLAGL1-targeting miRNAs (miR-98; 
miR-15a/16; miR-23a/b), leading to mRNA degradation, 
have been identified [35, 36]. Also it has to be taken into 
consideration the cellular organization of PLAGL1 gene 
transcription. Royo et al. demonstrated that PLAGL1 
mRNA accumulates juxtaposed to the nucleolus in 
normal fibroblasts, and that it is released from this nuclear 
compartment, increasing the synthesis of PLAGL1 protein, 
in response to stimuli that induce cell cycle arrest [37]. 
Thus the silmilar protein level between these two cell types 
is perhaps the result of less pronounced nucleolar retention 
of PLAGL1 transcripts in tumor cells than in normal 
fibroblasts. An alternative explanation may be that Western 
blot data is not appropriated for comparing the abundance 
of the PLAGL1 protein between different cell types, 
despite the growth conditions were identical. This seems to 
be supported by our findings from immunocytochemistry 
analyses, which indeed showed differences in terms 
of in situ expression of PLAGL1 protein in tumor cells 
(lower) compared to normal fibroblast (Figures 8 and 
9), suggesting that the level of PLAGL1 protein needed 
to control the proliferation of normal cells is different 
from that for tumor cells. Immunocytochemistry also 
revealed that the signal was only present in the cytoplasm 
of hepatoma cells, and this is in clear conflict with its 
nuclear functions as a transcription factor and cofactor of 
other proteins [38]. Alterations in the nuclear localization 
signal (NLS) domain of the protein may not be responsible 
for this cellular localization of PLAGL1, since mutations 
of this gene are uncommon in tumors (COSMIC; http://
cancer.sanger.ac.uk/cosmic). Instead, it is tempting to 
speculate that the defect may be due to abnormalities in 
Figure 11: Overexpression of PLAGL1 protein in HepG2 cells. (A) Immunofluorescence of transfected cells with antibody anti-
PLAGL1 (green). (B) Representative blots of PLAGL1 and p21 proteins. A protein extract from fibroblasts (Fibr.) was used as a signal 
control for the antibody p21. Actin was used as loading control. (C) PLAGL1 and p21 relative expression: Control 1 = T: 0 hs; Control 
2 = No plasmid; Control 3 = Empty plasmid; PLAGL1 = HepG2 cells transfected with the plasmid prk7-PLAGL1. Bars represent mean ± 
SD. Asterisks indicate statistically significant differences (***p < 0.0001). 
Oncotarget32789www.oncotarget.com
other players of the cellular trafficking, such us Importinα1 
(KPNA2) or Exportin1 (XPO1) [38, 39]. 
As mentioned before, PLAGL1 interacts with p53, 
and then the complex induces the expression of the p21 
gene, which is essential for controlling proliferation 
through cell cycle arrest [14, 16]. Therefore, we also 
profiled the genomic regions where these genes map. 
aCGH revealed that, except for SkHep1, the tumor cell 
lines do not harbour quantitative imbalances in the p53 
region (Table 1). PLAGL1 and p53 protein expression 
usually remained uniform during tumor-cells proliferation 
(Figure 7), but almost always at lower levels in HCC cells 
than normal fibroblasts. RT-qPCR studies demonstrated 
that p53 transcription is also rather constant during HCC 
cells proliferation, and this is in clear contrast with the 
dynamic transcription observed in normal fibroblasts 
(Figure 5). This cell-type exhibited the highest level of 
p53 mRNA at T: 0 h, which decreased to a minimum at 
48 h in culture and then increased again until the end 
of the experiment (T:96 h), similar to the transcription 
profile showed by PLAGL1 gene (Figure 5A), and it 
was accompanied by a reduction of the percentage of 
cells in G2/M phase conforming cell-cycle regulation 
takes place. Huang et al. demonstrated the interaction 
between PLAGL1 and p53 proteins, and proposed that 
both proteins participate together in the control of normal 
growth [14]. While Rozenfeld-Granot et al. reported 
that p53 acts as a transcription factor of PLAGL1 gene 
[40]. Now our study provides evidence for an apparent 
orchestrated transcription process of both genes during 
normal cells proliferation, which gets disturbed in HCC 
cells. The increase in the transcriptional activity may serve 
for maintaining constant the level of protein needed for 
cell-cycle regulation. Supportive evidence comes from 
our PLAGL1 overexpression studies. Transfection assays 
in PLC/PRF/5 and HepG2 cell-lines, with a construct 
that encodes the full-length protein, demonstrated that 
PLAGL1 level increased in cell transfected with prk7-
PLAGL1, respect to non-transfected cells (Figures 10 
and 11), and that the level of p21 protein increased only 
in HepG2, the cell-system with functional p53 gene. In 
spite of the fact that statistics showed that the differences 
were not significant, the data from cell count indicates 
that cell-growth lessened in both cell-types. Obviously, 
caution is warranted when interpreting these findings, 
but them suggest that abrogation of PLAGL1 function 
plays a role in HCC cells proliferation, like in other tumor 
types [20, 25, 31]. Moreover, one has to accommodate the 
fact that that PLC/PRF/5 cells with non-functional p53 
also underwent growth retardation, which indicates that 
PLAGL1 anti-proliferative activity is performed through 
additional mechanisms to those involving p53 and p21 
proteins. In fact, Varrault et al. have recently shown that 
PLAGL1 target genes include numerous genes involved 
in extracellular matrix composition, cell adhesion and cell 
signalling [41].
The genomic study revealed that the region 6p21.3, 
where p21 maps, showed gains of genetic material in 
SkHep1and HepG2, and losses in Huh7 (Table 1). Earlier 
studies performed by Koga et al. demonstrated, like us, that 
Huh7 cells have not detectable p21 expression (Figure 7E) 
[42], and most probably these results are consequence 
of the chromosome alteration in this cell line. The gain 
of genomic material in SkHep1 and HepG resulted in 
higher expression level of p21 in these cell-lines respect 
to PLC/PRF/5 cells, which does not harbour changes 
at 6p21.3 (Figure 1 and Table 1). However, statistical 
comparisons demonstrated that it is always lower than that 
of normal fibroblasts. This is in agreement with the data 
of immunocytochemistry analyses, which showed that the 
protein is hardly detected in the cytoplasm of tumor cells 
(Figure 8). The data of reduced expression of p21 during 
proliferation in HCC cell lines respect to non-tumoral 
cells, coinciding with low p53 mRNA and protein level, 
fit well with the antiproliferative function of these proteins 
[43–46]. However, dysregulation of the balance between 
proliferation and cell death cannot be explained only 
by a decrease in the expression level of a few proteins. 
Instead, the signalling pathways established during HCC 
cells growth are more complex, and our study shows that 
PLAGL1 plays an important role.
PLAGL1 also induces the transcription of the 
PPARy gene [47], and by its protein could inhibit cellular 
proliferation through p21 regulation [17, 48]. Therefore, 
we studied the transcriptional activity of the PPARy gene 
during cell proliferation. We found that after releasing 
cells from serum starvation, its mRNA level decreased 
respect to that found at T = 0 hs (Figure 5). Interestingly, 
only SkHep1 cells exhibited genomic losses at the region 
where PPARy maps, and consequently had the lowest 
level of PPARy transcripts respect to the other tumor cell-
lines (Table 1 and Figure 4C). This notwithstanding, the 
reduction of the transcript level is most likely related to 
its function as suppressor of cell division and survival 
[49–51]. However, some gene activity seems to be needed 
to maintain cell-adherence during proliferation, since 
it was demonstrated in HCC cells that treatment with 
PPARy inhibitors or gene silencing with small interfering 
RNAs cause cell detachment and anoikis [52, 53]. In this 
context, the low, but steady levels of PLAGL1 protein 
during HCC cells proliferation could also be associated 
with maintaining this necessary PPARy gene activity.
MATERIALS AND METHODS
Cell lines culture and tissue samples
The human hepatoma cell lines HepG2, Huh7, 
PLC/PRF/5 and SkHep1 derived from patients with HCC 
were acquired from American Type Culture Collection. 
Considering that the PLAGL1 expression level in fibroblasts 
and hepatocytes, are similar (http://genecards.org), 
Oncotarget32790www.oncotarget.com
normal fibroblasts at low passages established in our 
laboratory, were used as control. Cells were cultured in 
Dulbecco’s Modified Eagle’s Medium/Nutrient Mixture 
F-12 Ham (DMEM) (Sigma-Aldrich) containing 1% 
penicillin/streptomycin and 10% fetal bovine serum (FBS) 
(Invitrogen) at 37° C, constant humidity and 5% CO2. All 
experiments were performed with cells at low passages. 
Seven samples from patients with HCC, one 
with Cholangiocellular Carcinoma (CCC), two with 
Hepatoadenocarcinoma (HAC) and one with Focal 
Nodular Hyperplasia (FNH) were collected at the Italian 
Hospital of Buenos Aires in accordance with the ethical 
standards approved by the institutional Ethical Committee 
and the informed written consent of the patients. Liver 
tissue from patients without cancer was used as control.
The samples were preserved at −70º C until their use. 
Quantitative genomic aberrations by Array-
CGH analysis
DNA extraction was performed using a commercial 
kit, according to the manufacturer’s instructions (Qiagen). 
DNA from healthy individuals (Promega), was used 
as reference for the hybridization assays. Array-CGH 
(aCGH) analyses were performed as previously described 
by Royo et al. [54]. 
Methyl specific PCR (MS-PCR)
Genomic DNA from each tumor cell line (500ng), 
was subjected to bisulfite treatment, which converts 
unmethylated cytosines to uracils and leaves methylated 
cytosines unchanged, using the EZ DNA Mehtylation-
Direct kit (Zymo). Specific sets of primers for MS-
PCR, designed to amplify a region of the P1 promoter 
containing a methylated or unmethylated CpG island, were 
published by Leal et al. [55]. The PCR reaction contained 
200 µmol/L of dNTPs, 200 µmol/L of MgCl2, 100 ng of 
DNA, 200 pmol/L of primers and 0.5 µl of GoTaq in a 
final volume of 25 µl. While the PCR conditions were as 
follow: initial denaturing at 94° C for 3 min, 35 cycles 
at 94° C for 30 sec, 51° C for 45 sec and 72° C for 
30 sec, and a final extension for 5 min at 72° C. The PCR 
products were separated in a 10% polyacrylamide gel, 
stained with SYBR Green (0.0001% solution in loading 
buffer), and images were acquired in a gel documentation 
system equipped with a CCD camera.
Proliferation assays and flow cytometry
Each cell line was plated onto 75 cm2 flasks in 
DMEM medium containing 10% FBS, and cultured 
until reaching 80% confluence, and then the cells were 
incubated in DMEM medium containing 3% FBS for 24 h. 
After this period of cell synchronization, four flasks for 
each cell line were seeded with aliquots of 25 × 103 cells/ml 
and cultured in DMEM medium containing 10% FBS 
for 24, 48, 72 and 96 h, respectively. At each time point, 
the cells were harvested, aliquots were stained with 
trypan blue, and the number of viable cells determined 
in a Neubauer chamber. The doubling time (DT) and the 
constant rate of each cell line was determined using the 
exponential growth function (Y = Y0
*exp(k*X)). 
For cytometry analysis, an aliquot of cells from 
each time point of the proliferation curve was washed 
in PBS 1X and fixed in 1ml of ethanol 70% (ice-cold) 
for 30 min. Then, the cells were washed twice by 
centrifugation at 4000 rpm for 10 min at 4° C in PBS 1X. 
After centrifugation, the pellet was directly treated with 
a RNAse solution (100 µg/ml), and stained by adding 
400 µl of propidium iodide (2 µg/ml) per million cells 
during 15 min. The samples were then examined in a 
BD FACS Canto flow cytometer and the data analysis 
was performed with the FlowJo 10 computer program. 
All samples were analysed in duplicate of two biological 
replicates.
Quantitative RT-PCR 
Aliquots of the cells collected at each time point of 
the proliferation curve were used for RNA extraction by 
the TRIzol method (Invitrogen), according to the protocol 
provided by the manufacturer. RNA concentration was 
measured in a Nanophotometer TM P-Class (IMPLEN). 
Reverse transcription of 1µg of RNA to cDNA was 
performed using a commercial kit (Invitrogen) in a thermal 
cycler (Eppendorf). The conditions were as follow: 
incubation at 65° C for 5 min, followed by incubation at 
37° C for 52 min and at 72° C for 15 min.
To study the transcript level of the PLAGL1, p53 
and PPARy genes, aliquots of 70 ng of cDNA, 10µl of the 
MixSso (BIO-RAD), 1µl of the Probe + Primer 20X and 
2 µl of H2O were used for each reaction in an Opticon2 
instrument. The optimum quantity of cDNA (70 ng) 
for the detection of the transcripts and the efficiency of 
the technique was determined by the performance of 
the standard curve. To determine the efficiency of the 
technique, the slope of the line was calculated from the 
calibration assay of the standard curve of each transcript. 
This efficiency (≈90%) was obtained through the 
application of the formula: E = 10(-1/slope)-1. The conditions 
of the PCR were as follow: incubation at 96° C for 2 
min; followed by 50 cycles at 96° C for 15 sec, 60° C for 
1 min and 72° C for 1 min. Primers of PLAGL1 (Assay Nº 
H00414677_m1), p53 (Assay Nº H01034249_m1), PPARy 
(Assay NºH01115513_m1) and PPIA, the reference gene, 
(Assay Reagents Human PPIA P.N. 4333763F), were 
synthesized by Life Technologies. All samples were 
analysed in triplicate from two biological replicates. 
The analysis of the data was performed using the DNA 
Engine Opticon2 software (Gene Expression Analysis 
for iCycleriQ Real Time PCR detection System – BIO-
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RAD). For each gene, in each sample, a value of threshold 
cycle (Ct) was obtained, established as the number of 
cycles in which the reaction reaches the value of 0.02 of 
fluorescence intensity. This value of Ct corresponds to 
the average of the three values obtained in the technical 
replicates. The transcript level of PLAGL1, p53, PPARy 
and PPIA was quantified using the 2-ΔΔCt method (ΔΔCt = 
[CtTarget gene– CtPPIA]experiment − [CtTarget gene– CtPPIA]control).
Western blot
Aliquots of cells from each time point of the 
proliferation curve were washed by centrifugation in PBS 
1X, treated with lysis buffer containing 50 mM of Heppes, 
150 mM of NaCl, 0.5 mM of EDTA, 1% of Nonidet P-40 
and 10 µl of protease inhibitors/1 ml of buffer (100X, 
Thermo Scientific) for 30 min and centrifuged at 12000 
rpm for 30 min at 4° C. The concentration of proteins in 
the total lysate was determined by the Bradford protein 
assay. The Bradford reagent consists of 1 volume of 0.02% 
Coomassie Brilliant Blue (G-250) dissolved in ethanol, 2 
volumes of H3PO4 and 17 volumes of distilled water. The 
calibration curve for this assay was prepared with serial 
dilutions of bovine serum albumin. The solution for each 
measurement contained 10 µl of total lysate, 10 µl of 
distilled water and 200 µl of Bradford reagent. Once the 
protein concentration was determined, aliquots of 10 µg of 
total lysate were mixed with loading buffer, heated at 95° C 
for 5 min, and then loaded onto 10% SDS-polyacrylamide 
gel and separated at 100 V during 90 min. Then, the 
proteins were transferred onto 0.45 µm nitrocellulose 
membrane, blocked in 5% milk overnight at 4° C and 
then incubated 2 hours with primary antibody anti-
PLAGL1 (1:500, sc-22811, Santa Cruz Biotechnology), 
anti-p53 (1:500, sc-1311, Santa Cruz Biotechnology) and 
anti-p21 (1:500, sc-397, Santa Cruz Biotechnology). After 
hybridization with primary antibody, the membrane was 
washed with Tris-buffered saline containing Tween-20 
three times, then incubated with horseradish peroxidase-
labeled secondary antibody (Santa Cruz Biotechnology) 
for 1 hour at room temperature and washed with Tris-
buffered saline containing Tween-20 three times. Final 
detection was performed with ECL Chemiluminescent 
Western blotting reagents (Thermo Fisher Scientific). 
An antibody against Actin (1:500, sc-1615, Santa Cruz 
Biotechnology) was used for gel-loading control. Western 
blot signals were quantified using ImageJ program. The 
intensity of each band was normalized respect to that of 
actin (loading control) at the same time point. The assay 
was performed from two biological replicates.
PLAGL1 expression in situ
To study the expression level of PLAGL1 and p21 
proteins in situ, we performed immunofluorescence, 
immunocytochemistry and immunohystochemistry. 
The cell-lines were grown directly onto glass coverslips 
under the same conditions used for the other assays and 
harvested simultaneously with the cells used for qRT-
PCR and Western blot. The coverslips were washed in 
PBS 1X, and the cells fixed in paraformaldehyde (2% 
in PBS 1X) at 4° C for 15 min. Endogenous peroxidase 
activity was quenched by the incubation of the slides in 
4% hydrogen peroxide solution in PBS 1X for 40 min. 
The slides were washed in PBS 1X and incubated for 
1 h in 3% bovine serum albumin to block unspecific 
sites, and then incubated with a 1:100 dilution of anti-
human PLAGL1 and anti-human p21 overnight at 4° C. 
The detection was performed with a 1:200 dilution of 
secondary antibody conjugated to HRP for 1 h at room 
temperature. Then, slides were washed in PBS 1X and 
developed in 3,3′-diaminobenzidine (Liquid DAB + 
Substrate Chromogen System, Cell Marque). Cells were 
counterstained in Mayer’s hematoxylin, washed in PBS 
1X, dehydrated in an ethanol series, cleared in xylene, and 
mounted with a solvent-based mounting medium (ALUN 
Metraquímica). All cell lines were stained in duplicates, 
and negative controls were prepared by excluding the 
primary antibodies in the procedure.
For immunofluorescence, the coveslips were 
treated similarly but excluding the incubation in hydrogen 
peroxide, using secondary antibodies conjugated to Alexa 
Fluor 546 (red) and Alexa Fluor 488 (green) and mounted 
with Vectashield-DAPI®.
PLAGL1 immunoreactivity was also analysed in 
11 tissue-samples from patients with hepatic tumors, as 
well as non-tumoral liver tissue. Immunohistochemistry 
was performed on 4 µm thick paraffin sections that were 
deparaffinized and rehydrated in an ethanol series. Antigen 
retrieval was carried out by microwaving for 15 min in 
citrate buffer, pH 6.0 (10 mM citric acid, 10 mM sodium 
citrate), cooled and washed twice in PBS 1X for 5 min. 
The histological preparations were permeabilized with 
0.05% Triton in PBS 1X, washed once in PBS 1X and next 
incubated in 4% hydrogen peroxide solution in PBS 1X for 
40 min. Then, the same antibodies treatment and detection 
procedure were used as described before. The immunostained 
sections were evaluated using a Olympus light microscope. 
Protein immunostaining intensity was scored as: strong 
(+++), moderate (++), weak (+) and negative (−).
PLAGL1 protein overexpression
To study the effect of PLAGL1 overexpression 
on HCC cells proliferation, we performed transfection 
assays in the PLC/PRF/5 and HepG2 cell lines with the 
plasmid prk7-PLAGL1 (kindly provided by Dr Laurent 
Journot, Institut de Genomique Fonctionnelle, Universite 
de Montpellier, France) [56]. These cell lines were chosen 
because HepG2 is normal as regard to p53 gene, while 
PLC/PRF/5 presents a mutation in this gene (R249S) 
that encodes for a non-functional p53 protein. Aliquots 
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of 5 × 104 cells were cultured onto 6-well plates in 
complete DMEM medium for 72 h. At this time point (T 
= 0 hs; 70% confluence), the cells were transfected with 
the plasmid prk7-PLAGL1, using Lipofectamine 2000 
(Invitrogen) following the manufacturer’s protocol. After 
a transfection period (6 hs) without sera, the medium was 
replaced by DMEM containing 10% FBS and incubated 
for 30 aditional hs. Controls included non-transfected 
cells harvested at T = 0 hs and T = 30 hs, as well as cells 
transfected with the empty vector plasmid. 
The cells from each experimental condition were 
harvested, aliquots were stained with trypan blue, and the 
number of viable cells determined in a Neubauer chamber. 
PLAGL1 and p21 proteins levels were determined by 
Western blot and inmunfluorescence following the 
protocol described above. The experiments were carried 
out in duplicate.
Statistics
All statistical analysis and graph were performed 
with Graph Pad Prism v.5.0. Comparisons between 
samples were evaluated with analysis of variance 
(ANOVA). Diferences between results were considered 
significant if the p-value was < 0.05 (*); < 0.001 (**) and 
< 0.0001 (***).
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